Phase III Gazyva Trial Fails to Meet Primary Endpoint of Improving PFS in DLBCL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A phase III study evaluating Gazyva (obinutuzumab) plus CHOP chemotherapy in people with previously untreated diffuse large B-cell lymphoma did not meet its primary endpoint of progression-free survival compared to Rituxan (rituximab) plus CHOP chemotherapy, according to Genentech, a member of the Roche Group.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone, a chemotherapy regimen, in adult patients with newly diagnosed stage 2b with risk factors/3/4 Hodgkin lymphoma.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login